Who
Barbara Gayle Duncan
Director
Company insider
Files Form 4 as: Director, Atea Pharmaceuticals; Director, Halozyme Therapeutics; Director, Ovid Therapeutics; Director, Fusion Pharmaceuticals; Director, Jounce Therapeutics; Director, Adaptimmune Therapeutics; Director, Immunomedics; Director, Aevi Genomic Medicine.
In numbers
- Trades disclosed
- 242
- Buys
- 1
- Sells
- 24
- Bought
- $75K
- Sold
- $7.4M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 30 Jun 2006
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,600 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,200 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,165 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.